Critical Review

A Review and Analysis of Managing Commonly Seen Implanted Devices for Patients Undergoing Radiation Therapy

Maria F. Chan, PhD, a, * Claire Young, MS, CMD, a Daphna Gelblum, MD, b Chengyu Shi, PhD, c Carollane Rincon, BSN, RN, OCN, b Elizabeth Hipp, PhD, a Jingdong Li, PhD, a and Dongxu Wang, PhD a

a Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY; b Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; c Department of Medical Physics, New York Proton Center, New York, NY

Received October 1, 2020; revised March 28, 2021; accepted April 19, 2021

Abstract

Purpose: This review article aims to consolidate information regarding existing and emerging implanted devices used in patients undergoing radiation therapy and to categorize levels of attention needed for each device, including which devices require monitoring throughout treatment.

Methods and Materials: Based on the collective information from scholar searches, manufacturers’ technical reports, and institutional experiences in the past years, commonly present devices in patients with cancer are compiled. This work summarizes cardiac pacemaker, implanted cardiac defibrillator, hepatic pump, intrathecal pain pump, neurostimulator, shunt, loop recorder, and mediport. Three different classifications of implanted devices can be made based on the potential effect of radiation: life-dependent, nonlife-dependent but with adverse effects if overdosed, and devices without electronic circuits. Implanted devices that contain electronic circuits that would be life-dependent or have adverse effects if overdosed, include cardiac pacemakers, implanted cardiac defibrillators, programmable hepatic pumps, pain pumps, neurostimulators, and loop recorders.

Results: Dose exposure to these devices need to be calculated or measured in vivo, especially for cardiac implanted devices, and they should be minimized to assure continued healthy functioning. Treatment planning techniques should be chosen to reduce entry, exit and internal scatter dose. Lower energy photon beams should be used to decrease potential neutron contamination. Implanted devices without electronic circuits are less of a concern. If a patient is life-dependent on the implanted device, it is not recommended to treat the patient with proton therapy.

Conclusions: This study reviewed the management of patients with commonly seen implanted devices and summarized a workflow for identifying and planning when a patient has implanted devices. Classifications of implanted devices could help clinicians make proper decisions in regard to patients with specific implanted devices. Lastly, the management of such devices in the era of the pandemic is also discussed in this review article.

Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Sources of support: This research was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.

Disclosures: M. Chan has a research grant from Ashland Inc, the manufacturer of GafChromic film. D. Wang reports receiving royalty and licensing fees from Ion Beam Applications, SA. Both were outside the submitted work. The authors declare that they have read the article and there are no competing interests.

Data Sharing Statement: Research data are not available at this time.

Note—a online CME test for this article can be taken at https://academy.astro.org.

*Corresponding author: Maria F. Chan, PhD; E-mail: chanm@mskcc.org

https://doi.org/10.1016/j.adro.2021.100732
2452-1094/Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

The use of implanted devices has increased progressively in the 30 years since the first implantable cardioverter-defibrillator (ICD) was released commercially in the United States. Pacemakers and ICDs are among the top 5 most frequently implanted medical devices beside artificial hips, breast implants, and spine screws/rods/discs in the United States. As the number of patients with implanted devices (IDs) increases, radiation therapy clinics are seeing proportionally more patients with IDs, including those who have concurrent chemoradiation. Devices most commonly encountered in patients with cancer include cardiac pacemakers, ICDs, intrahepatic pumps, pain pumps, neurostimulators, shunts, loop recorders, and mediports.

Clinicians typically take counsel from the patient's cardiologist, electrophysiologist, or manufacturer of the ID before radiation treatment (RT) to create strategies unique to each patient for instrument monitoring and validating appropriate device functions. However, the effects of therapeutic radiation on IDs are often difficult to predict. A variety of factors may influence the effect of radiation therapy on ID, including ID type, proximity to the radiation beam, the dose being delivered to the device, energy of the radiation beam, the type of device, and delivery technique; does it function as a conduit or does it have circuitry with programming and memory (complementary metal oxide semiconductors [CMOS]).

Electronic devices can be damaged by various levels of high energy ionizing radiation. It has been observed that doses from RT induce malfunctions, including abnormal changes in pulse repetition frequency when implantable electronic devices are exposed to radiation. Therefore, it is important to identify, document, and account for the expected dose exposure during the treatment planning and beam delivery processes. It is essential to approximate the expected radiation dosage to the IDs.

Widely adopted guidelines from the 1990s, published in the British Journal of Radiology and by the American Association of Physicists in Medicine (AAPM), do not include some of the newer implanted devices in recent decades. The newly published AAPM TG-203 Report focuses mainly on the management of implantable cardiac pacemakers and defibrillators (cardiac implantable electronic devices [CIEDs]), but also provides some guidance on the management of patients with other implantable devices.

Conversely, a report from the Dutch Society of Radiation therapy and Oncology emphasizes the patients' perspective and the practical aspects of the safe management of patients with CIEDs. The AAPP TG-203 categorized CIEDs patients based on the CIED cumulative dose, pacing dependency and neutrons present into low, medium, and high-risk. The Dutch Society of Radiation therapy and Oncology report categorized CIED patients based only on the cumulative dose and patient dependency. This work assumes the adoption of such risk categorizations in practice.

Management of Commonly Seen Implanted Devices in RT Patients

We have compiled and reviewed management guidelines for IDs from different manufacturers and the range of dose tolerances of their devices. The most frequently seen IDs in patients undergoing RT are shown in Fig. 1. These include cardiac pacemakers (Medtronic, St. Jude Medical, Guidant/Boston Scientific), ICDs (Medtronic, St. Jude Medical, Guidant/Boston Scientific), intrahepatic pumps (Johnson & Johnson, Medtronic), intrathecal pump (Medtronic, Flowonix Medical), neurostimulators (Medtronic, St. Jude Medical, Guidant/Boston Scientific, LivaNova), cardiac loop recorders (Medtronic, St. Jude Medical), cerebral shunts (Aesculap, Medtronic, Sophysa), and mediports (Aesculap, AngioDynamics, Bard Medical).

Description of implanted devices

A cardiac pacemaker is usually placed in the chest or abdomen to help control abnormal heart rhythms. Some new leadless pacemakers are directly implanted into the right ventricular heart muscle. The pacemaker uses electrical pulses to prompt the heart to beat at a specified rate. An ICD is implantable in the subcutaneous tissues of the chest or abdomen. ICD performs cardioversion, defibrillation, and pacing of the heart, and corrects most life-threatening cardiac arrhythmias. Both pacemaker and defibrillator can be used in cardiac resynchronization therapy. A hepatic arterial infusion pump is a small, programmable device implanted in the abdominal cavity that is designed to deliver chemotherapy at a constant rate directly to the liver. This method allows for high doses of chemotherapy to be delivered to the liver with protection of the surrounding normal tissues. The pump is sensitive to heat, for example, the medication would flow faster if the surrounding temperature increases. An intrathecal pump directly delivers medications into the space between the spinal cord and the protective sheath surrounding the spinal cord. Radiation could cause alarm and failure of the pump due to electronic circuit damage or battery depletion. An implantable neurostimulation device modulates the nervous system's activity, usually through electromagnetic approaches. Similar to CIEDs, the neurostimulator also

Based on the searches in literature databases such as PubMed/ScienceDirect, this article represents the first addressing a variety of IDs commonly seen in patients undergoing RT, consolidating their corresponding dosimetric tolerances, and addressing adaptive management during Coronavirus disease 2019 pandemic in a single resource. This work aims to provide a general review of existing and newly emerging IDs and recommends planning considerations for each one.
has a pulse generator component, which can be potentially damaged by radiation.10-12 A loop recorder records and remotely reports heart rhythm continuously or, on-demand, for up to 3 years. It is a small device inserted just beneath the skin of the chest to capture the electrical signals of the heart. Alike CIEDs, the loop recorder also has CMOS electronic circuitry that could have radiation-induced effects.5 A cerebral shunt is commonly used to treat hydrocephalus, the swelling of the brain due to excess buildup of cerebrospinal fluid. They are catheters that redirect the fluid from the ventricles typically into the heart or abdomen where it can be absorbed.21 A mediport is a small, implantable reservoir that allows chemotherapy medications to be delivered through the port.22 Both cerebral shunt and mediport do not have an electronic circuitry component in them. A tubeless insulin pump is a newer device, which is programmed to cover basic insulin needs by regularly delivering small amounts of short-acting insulin or extra amounts at mealtimes as needed. We will not discuss more on this device in this article as it is attached externally to the patient; however, it is advised that patients remove these devices for radiation therapy delivery.

A leadless pacemaker serves the same function as a traditional pacemaker, but without the lead. Instead, the leadless pacemaker is transvenously placed into the myocardium at the right ventricle. The dose limit and effect stay the same as a traditional pacemaker.28 The intramural cardiac positioning of the device makes monitoring its exposure more challenging and less likely to be repositioning. Often, as can be seen in Fig. 2 in a clinical case at the authors’ institution, a leadless pacemaker placed into the right ventricle can be very close to the irradiated volume for a patient with left-breast cancer. Unlike a traditional pacemaker which can be moved to a distal location if necessary, the treatment plan has to be carefully designed to minimize doses to the leadless pacemaker. In any case, the simulation scan should include the level of the device so a dose estimation can be calculated as an in vivo measurement is impossible (Fig. 2).

**Categorizing the implanted devices**

Usually, IDs are identified during the initial radiation oncology consultation in the patient’s self-reporting questionnaire or the nursing review. When an ID is reported, a copy of both sides of the patient’s device identification card is obtained and stored in the patient’s electronic medical record if available. Three different classifications of implanted devices can be made based on the effect of radiation: life-dependent, nonlife-dependent but with adverse effects if overdosed (adverse), and devices without electronic circuits (without circuits). We classify each category based on their potential malfunctions due to radiation and the effects to the patient in case of malfunctions.

**Factors affecting implanted devices**

Multiple studies18,19,29,30 report on factors determining the effect of therapeutic radiation on implanted devices. These factors include device type, proximity to radiation field, radiation energy and modality, radiation beam orientation, dose rate, cumulative dose, shielding, patient anatomy and physiology, frequency of radiation treatment, and any concurrent therapy or diagnosis. Some
clinical studies provided clinical perspectives on the effects of ionizing radiation. Zaremba et al. reported that CIED malfunctions were seen in ~ 3% of RT courses, and typically consisted of transient software disturbances and only rarely presented permanent damage to the device. Ahmed et al. reported a case of full-dose chemoradiotherapy to lung cancer where an ICD was located within the irradiating field. As the patient was not ICD-dependent; he was treated with the ICD in its original location with a mean dose of 29.3 Gy to the device, much higher than the recommended limit. This patient successfully went through the entire RT course without experiencing or reporting cardiac symptoms.

Owing to the variability of the many factors, it is accepted that there is not a single safe radiation dosage to a given family of devices. Similar to the ALARA (“as low as reasonably achievable”) principle for personnel exposure management, effort should be made to minimize dose to the IDs, through the shielding of the device if possible, or the optimal designing of the treatment plan. The absorbed dose to be received by the device should be calculated. Practically, a dose limit would still be useful. Some clinical studies provide a recommended maximum total dose of 2 Gy to the implanted device. A recent review article showed that the strongest predictive factors of CIED malfunction are higher radiation doses and higher beam energy given the concern for neutron production. Most device manufacturers provide their own recommendations on dose tolerances depending on the device/model. The AAPM TG-203 provides

patient risk categories also based on cumulative dose (<2 Gy, 2-5 Gy, >5 Gy) to the CIED and pacing independent versus pacing dependent. All manufacturers recommend relocating the device generator outside the radiation field; however, relocation may not be required for devices receiving a cumulative dose <5 Gy. Some vendors such as St. Jude Medical/Boston Scientific will not guarantee zero risk of malfunctions at any dose level. A recent study also reported that adverse clinical events can occur in any group of risk and no dose-dependency was observed on the CIED malfunction. Another study confirmed that lung stereotactic ablative radiation therapy is safe for CIEDs when the dose is kept <2 Gy and beam energy is <10 MV, regardless of the pacing-dependency and the CIED type. A retrospective study found that all single-event upset malfunctions occurred in the setting of neutron production, with 21% for neutron-producing RT (ie, 15 MV or 18 MV) and 0% for non-neutron-producing RT (ie, electrons, Gamma Knife, or 6 MV).

**Dose limits of implanted devices and in vivo measurement**

Table 1 lists the commonly used implanted devices and their functions, categories, and recommended dose limits. Previous studies have revealed that higher energy radiation (ie, >10 MV) will cause more IDs to experience electric malfunction; as a result,
| Implanted device      | Clinical use                          | Susceptible component | Category       | Dose limit | Historical malfunctions reported                                                                 | References |
|-----------------------|---------------------------------------|-----------------------|----------------|------------|-------------------------------------------------------------------------------------------------|------------|
| Pacemaker             | Control heartbeat                     | CMOS, RAM, Battery    | Life-dependent | 2-5 Gy     | Transient damage, Permanent damage, EC damage, Parameter reset, Signal interference, Battery depletion | 8,9,18,19, 33,38,46 |
| ICD                   | Sends electrical signals to the heart | CMOS, RAM, Battery    | Life-dependent | 0.5-2 Gy   | Transient damage, Permanent damage, Pacing pulse change, Pacing frequency change, Sensing threshold change, Lead impedance change, Loss of telemetry capability, Loss of signal/data, Battery depletion | 8,14,18,19, 33,38,39 |
| Programmable hepatic pump | Gives continual chemotherapy to the liver | EC, Battery           | Adverse        | 10 Gy*     | NA                                                                                           | 20         |
| Intrathecal pain pump | Gives continual pain medication to spine | EC, Battery           | Adverse        | 28.5 Gy    | EC damage, Battery depletion, Pump alarm                                                      | 4,13       |
| Neurostimulator       | Sends electrical signals to the brain and spine | Implantable pulse generator | Adverse        | 5 Gy       | NA                                                                                           | 10,11,12   |
| Loop recorder         | Monitors heart rhythm                 | CMOS, Battery         | Adverse        | 5 Gy†      | NA                                                                                           | 5,39       |
| Mediport              | Vein access point for chemotherapy, IV, etc | NA                   | Without circuits | NA         | NA                                                                                           | 22         |
| Cerebral shunt        | Drains excess CSF from brain          | NA                   | Without circuits | NA         | NA                                                                                           | 21         |

*Abbreviations: CMOS = complementary metal oxide semiconductors; CSF = cerebrospinal fluid; EC = electronic circuit; IV = intravenous; NA = not applicable.  
* Private communication from the manufacturer, Medtronic, Minneapolis, MN, October 23, 2019.  
† A conversation needed with the cardiologist on the fidelity of the information retrievable after radiation.
devices with electronic circuits should be treated with low energy (ie, $<$10 MV photons) only. Because both severity and risk of failure of devices from dose rate effects are mild and low, the AAPM TG-203 recommends a dose rate of $<$0.2 Gy/min as guidance. A recent study investigated the effects of x-ray dose rates of 4 to 24 Gy/min on CIED function and found that a dose rate $>$8 Gy/min would cause a temporary malfunction due to interference. It had been recommended that in low-risk patients with the presence of an ICD and medium-risk patients with CIED, a weekly device check during the RT is recommended. In high-risk patients, device evaluation within 24 hours after each fraction is needed. Given the potential device malfunction, a close collaboration among cardiologist, radiation oncologist, and physicist is necessary to minimize the risk to patients. Any in vivo dosimetry system (eg, optically stimulated luminescence dosimeter [OSLD], thermoluminescent dosimeter [TLD], diodes, etc) may be used on the first day of treatment to measure the daily or fractional dose the device receives, and calculate the cumulative dose expected over the course of treatment. The use of different in vivo dosimeters for out-of-field measurements requires knowing the detector sensitivity as a function of off-axis distance; an out-of-field calibration for the detector in use is recommended in addition to other considerations and requirements about out-of-field dosimetry at CIED depths. Depending on the spatial distance between the radiation field edges and the most proximal part of the ID, different approaches can be used to reduce radiation exposure to the IDs.

**Fig. 3** A sample workflow to handle implanted devices.

**Treatment planning of patients with implanted devices**

A systematic policy in identifying ID-bearing patients should be integrated with early treatment planning procedures. A possible workflow is illustrated in Fig. 3. Electronic device presence should be documented in a patient’s electronic medical record or the health care information system, where dosimetrists should check for information regarding devices and act accordingly throughout treatment planning. This will help dosimetrists recognize newly emerging devices and avoid damaging them, thereby preventing adverse effects.

During the treatment planning process, implanted devices should be contoured as a structure to be optimized for a lower dose. For patient setup verification, imaging fields should be angled to minimize exposure to the devices, and if necessary, the collimator for pretreatment kV imaging should be adjusted to block the direct entrance of x-rays for the same consideration. If the device sits within 5 cm proximal to the field edge, a bolus (1-2 cm thickness) on the top of the device for the entire course of treatment minimizes scatter and leakage because the photon spectra outside the treatment fields are in the kV range. Chan et al reported that placement of bolus on the top of the ICD would reduce the dose to the device by 34% to 58% depending on the distance from the edge of the field. Treatment planning techniques such as coplanar beam arrangement can also reduce entry and exit through the device. Lower energy photon beams should be used to eliminate neutron contamination that could reset the read-only memory state of the device.
Patients undergoing proton therapy

Patients with CIED may be treated with proton therapy; however, the risk should be evaluated together with the patient’s cardiologist before treatment start. Gomez et al reported that 23.6% of patients with CIEDs receiving proton therapy were for thoracic tumors from March 2009 to July 2012 and 20% of the patients experienced CIED resets.45 There was also a report that CIED reset can occur despite not being detected by electrocardiogram monitoring; instead, it was uncovered by posttreatment programmer analysis.46 Modern CIEDs have CMOS which can tolerate doses of more than 2 Gy47,48; however, the proton machine design has an effect on the CIED due to the overall physical environment around the patient. The pencil beam scanning system creates a relatively strong magnetic field around the patient, which may induce CIED malfunction.17 Therefore, each patient needs to be considered individually and recognized of the patient’s dependence on the CIED identified. If the patient is pacing-dependent, it is usually not recommended to treat them with proton therapy,45,46,49 especially in standalone centers with limited resources. Likewise, for the pacing independent patient, risks should be evaluated before delivering proton therapy. For low-risk patients whose accumulative dose from proton therapy plan on CIED <2 Gy, the patient will be instructed to report any symptoms of cardiac nature. For medium-risk patients, a cardiology expert should be present during the treatment and check the CIED function before and after the treatment.8 High-risk patients should be monitored during every fraction and the pacemaker should be checked before and after treatment by CIED technician. The patient should be further checked by CIED technician after the proton therapy at a frequency of 1, 3, and 6 months.8 If possible, the dose should be measured with a phantom for the proton therapy plan, and the patient should have an in vivo measurement (eg, OSLD, TLD, diodes, etc) during the treatment.50 In summary, because the modality has a higher risk of generating secondary neutron contamination and complex electromagnetic interference, a detailed plan should be created to include a multidisciplinary treating team, cardiologist, and CIED technician before the patient receives proton therapy. Patients with implanted cardiac loop recorders can be treated with both photon and proton therapy but the device would preferentially not be in the direct radiation beam. Loop recorders have a reported tolerance of 5 Gy before corrupting. Even with lower dose exposures, it is very possible that the arrhythmia detection will be harmed at least during the time of radiation therapy delivery. It is also possible that detection after completion of RT delivery will also be corrupted and this needs to be discussed with the patient's cardiologist.5

Patients with Non-CIED IDs

The management of patients with other programmable implanted devices such as hepatic pump,40 intrathecal pain pump,4,13 and neurostimulators10-12 should be comparable to that of CIED patients due to having electronic circuitry, battery, or pulse generator. Similarly, these devices carry dose limits to avoid radiation-induced failure of the device. A programmable hepatic pump has a dose tolerance being 10 Gy as per the manufacturer and the medication would flow faster when the body temperature rises.20 Similarly, a programmable intrathecal pain pump might malfunction if cumulative doses were above 28.5 Gy as reported in one case.13 Any patient with an infusion pump undergoing radiation therapy should be alerted for possible pump’s alarm sounding during treatment. Pump functionality assessment should be conducted after radiation treatment.4 Neurostimulator typically consists of an implantable pulse generator, electrode array, and insulating wiring connecting the electrodes to the generator. A dose limit of 5 Gy was recommended, and the pulse generator should be kept away at least 1 cm from the radiation field edge.10 All of them also require a multidisciplinary approach before radiation therapy delivery. On the other hand, mediport,22 and cerebral shunt21 are without electronic circuitry, and they are less of a concern in terms of dose tolerances. However, during radiation therapy care must be taken to prevent potential infection and obstruction of the devices. In addition, most implanted devices use CMOS technology to produce integrated circuits that are sensitive to radiation. Nowadays the majority of devices equipped with improved CMOS circuitry (more radioresistant) such as thin CMOS gates (<1.5 μm), those devices would tolerate a higher cumulative dose and dose rate (ie, 10 Gy and 0.2 Gy/min).18,19,51,52 However, because the susceptibility of an implanted device is very dependent on the underlying integrated circuit technology, which varies among different subsystems and models, whether to go beyond the common practice guideline (2 Gy) should be personalized. Future studies can be built on the findings of existing reports and perform risk-based analysis, and thereby recommend refining workflows on clinical management of patients with such emerging devices.

Management of RT patients with implanted devices in a pandemic

There have recently been many publications on the oncologic care of patients in the setting of the new Coronavirus disease 2019 pandemic.53,54 The primary focus of these reports is the protection of the patients and the health care staff from possible exposure to the virus from an unrecognized carrier. In the entire network of the authors’ institution,
we have implemented strategies to minimize the patient time in the department, contact between patients and staff, and to reduce the number of visits a patient will need to make into the cancer clinic. There are certain patient care interventions that require extended time with the patient or may require a physician or medical physics staff presence in the patient care environment. One such situation is the management of a patient with a CIED. As required, a conversation needs to be had with the patient’s electrophysiologist or cardiologist to determine whether the device has been interrogated in the past 6 months and is in working order as well as the degree of the patient’s dependence on the device. This will help guide the indications for midtreatment device interrogation and safe patient handling.55,56 Similarly, every effort should be made to design RT fields that avoid the IDs and a plan which uses <10 MV photons to minimize the risk of any neutron production and scatter.

The AAPM TG-203 guideline18 helps reduce the duration of direct patient interaction by offering a classification of low-, medium-, and high-risk patients based primarily on the distance of the treatment field from the device, as well as energy used and pacing dependency. This strategy was well used during the pandemic when attempting to shorten time with patients and to only take actual dose measurements with OSLDs or TLDs on the patient for situations in which the radiation field edge was in close proximity to the CIED. For treatment fields positioned further away from the devices, the dose to the device can be estimated by medical physicists if the site has been included in the simulation scan. As the placement of cardiac leads to monitor a patient during their first fraction requires working near the head of the patient, it is important that the patient and the health care worker both wear protective masks. We suggest in addition to these measures, that cardiac monitoring of the patient is completed remotely to the machine if possible, to minimize the crowding of health care professionals at the treatment console. One should try to use video-streaming devices to project the rhythm strip from the room to the licensed independent practitioner assigned to monitor the patient while treatment is delivered. This practice permits the practitioner to be located at some distance from the rest of the treatment team. To view the strip reliably, this also requires that the gain be increased as much as possible on the electrocardiogram display so the tracing can be accurately monitored. Post radiation treatment management remains the same with the patient returning to their electrophysiologist shortly after completing radiation to have the device retested and confirm continued proper functioning.

Conclusions

This study provides an easily accessible reference to practical dose limits for IDs for radiation oncology staff, the uses for these devices, and manufacturers were identified. The radiation dose tolerances to the devices were collected and they can differ among varying models and manufacturers. We summarized a workflow for identifying and planning when a patient has IDs included cardiac pacemaker, ICD, hepatic pump, pain pump, neurostimulator, shunt, loop recorder, and mediport. Classifications of implanted devices into 3 categories—life-dependent, nonlife-dependent but with adverse effects if overdosed, devices without electronic circuits—could help clinicians make a proper decision to a radiation therapy patient with specific implanted devices.

Acknowledgments

This research was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.

References

1. McIntyre DA. 24/7 Wall St. Available at: https://247wallst.com/healthcare-economy/2011/07/18/the-eleven-most-implanted-medical-devices-in-america/. Accessed March 26, 2020.
2. Riva G, Alessandro O, Spoto R, et al. Radiotherapy in patients with cardiac implantable electronic devices: Clinical and dosimetric aspects. Med Oncol. 2018;17:73.
3. Malavasi VL, De Marco G, Imberti JF, et al. Radiotherapy-induced malfunctions of cardiac implantable electronic devices in cancer patients. Intern Emerg Med. 2020;15:967–973.
4. Bak K, Gutierrez E, Lockhart E, et al. Use of continuous infusion pumps during radiation treatment. J Oncol Pract. 2013;9:107–111.
5. de Sousa M, Klein G, Korte T, et al. Electromagnetic interference in patients with implanted cardioverter-defibrillators and implantable loop recorders. Indian Pacing Electrophysiol J. 2002;2:79–84.
6. Lauro C, Miften M, Albano E, et al. Intact functioning of intrathecal pain pump receiving radiation therapy. J Clin Case Rep. 2012;2:157.
7. Gebhardt R, Ludwig M, Kirner S, et al. Implanted intrathecal drug delivery systems and radiation treatment. Pain Med. 2013;14:398–402.
8. Salerno F, Gomellini S, Caruso C, et al. Management of radiation therapy patients with cardiac defibrillator or pacemaker. Radiol Med. 2016;121:515–520.
9. Wadasadawala T, Pandey A, Agarwal JP, et al. Radiation therapy with implanted cardiac pacemaker devices: A clinical and dosimetric analysis of patients and proposed precautions. Clin Oncol. 2011;23:79–85.
10. Walsh L, Guha D, Purdie TG, et al. Spinal cord stimulators and radiotherapy: First case report and practice guidelines. Radiat Oncol. 2011;6:143.
11. Guy J, Levy A, Malkoun N, et al. Preventing radiotherapy: Induced side effects on deep brain stimulators: The need for a multidisciplinary management. Br J Neurosurg. 2013;28:107–109.
12. Gossman MS, Keitkar A, Liu AK, et al. Vagus nerve stimulator stability and interference on radiation oncology x-ray beams. Phys Med Biol. 2012;57:N365–N376.
13. Wu H, Wang D. Radiation-induced alarm and failure of an implanted programmable intrathecal pump. Clin J Pain. 2007;23:9.
16. Last A. Radiotherapy in patients with cardiac pacemakers. *Br J Radiol.* 1998;71:4-10.

17. Marbach JR, Sontag MR, Van Dyk J, Wollbarst AB. Management of radiation oncology patients with implanted pacemakers. *AAPM Task Group Report*. 1994.

18. Miften M, Mihailidis D, Kry SF, et al. Management of radiation therapy patients with implanted cardiac pacemakers and defibrillators: A Report of the AAPM TG-203. *Med Phys.* 2019;46:e757–788.

19. Hurkmans CW, Kneegjens JL, Oei BS, et al. Management of radiation oncology patients with a pacemaker or ICD: A new comprehensive practical guidelines in The Netherlands. *Radioth Oncol.* 2012;7:198.

20. Memorial Sloan Kettering Cancer Center. Available at: https://www.mskcc.org/cancer-care/patient-education/about-your-medtronic-implanted-infusion-pump. Accessed August 26, 2020.

21. Memorial Sloan Kettering Cancer Center. Available at: https://www.mskcc.org/cancer-care/patient-education/about-your-ventriculoperitoneal-vp-shunt-surgery. Accessed August 26, 2020.

22. Memorial Sloan Kettering Cancer Center. Available at: https://www.mskcc.org/cancer-care/patient-education/your-implanted-port. Accessed August 26, 2020.

23. National Institutes of Health. Available at: https://www.nlm.nih.gov/health-topics/pacemakers. Accessed August 26, 2020.

24. National Institutes of Health. Available at: https://medlineplus.gov/ency/article/007370.htm. Accessed August 26, 2020.

25. Mayo Clinic. Available at: https://www.mayoclinic.org/tests-procedures/implantable-loop-recorder/pcy-20384986. Accessed August 26, 2020.

26. St. Jude Medical. Available at: https://www.medicalxpo.com/prod/st-jude-medical/product-70886-527459.html. Accessed August 26, 2020.

27. Adler JA, Lotz NM. Intrathecal pain management: A team-based approach. *J Pain Res.* 2017;10:2565–2575.

28. Medtronic, Inc. Radiotherapy CRHF technical services standard letter. 2016. Available at: https://www.medtronic.com/crs-upload/letters/99/99_CQES-IPG-Standard-Letter-RadiationTherapy-Micra-2016-Sep26.pdf. Accessed August 26, 2020.

29. Indik JH, Gimbel R, Abe H, et al. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. *Heart Rhythm*. 2017;14:e97–e153.

30. Boston Scientific Report. Therapeutic radiation and implantable device systems. 2012. Available at: https://www.bostonscientific.com/content/dam/bostonscientific/quality/education-resources/ english-a4/EN_ACL_Therapeutic_Radiation_20120925.pdf. Accessed August 26, 2020.

31. Kobayashi H, Shiraiishi K, Tsuchiya H, et al. Soft Errors in SRAM Devices Induced by High Energy Neutrons, Thermal Neutrons and Alpha Particles. *Electron Devices Meeting*. 2002:337–340. *IEDM Digest, International*. 2002.

32. Wilkinson JD, Bounds C, Brown T, et al. Cancer-radiotherapy equipment as a cause of soft errors in electronic equipment. *IEEE Transactions on Device and Materials Reliability*. 2005;5:449–451.

33. Zaremba T, Jakobsen AR, Sogard M, et al. Radiotherapy in patients with pacemakers and implantable cardioverter defibrillators: A literature review. *European*. 2015;18:479–491.

34. Ahmed I, Zhou W, Jabbour SK. High dose radiotherapy to automated implantable cardioverter-defibrillator: A case report and review of the literature. *Case Report*. 2014 988957.

35. Luca F, Parrini L, Cipolletta L, et al. Radiotherapy and devices in cancer patients: What is new in clinical practice? *Int J Heart Rhythm*. 2019;4:4–13.

36. López-Honrubia V, Hidalgo-Olivares VM, Dobón-Roux M, et al. Radiotherapy is safe in patients with implantable cardiac devices. *Analysis of a systematic interrogation follow-up. Clin Transl Oncol.* 2020;22:2286–2292.

37. Levis M, Andreis A, Badellino S, et al. Safety of lung stereotactic ablative radiotherapy for the functioning of cardiac implantable electronic devices. *Radiother Oncol.* 2020;156:193–198.

38. Grant JD, Jensen GL, Tang C, et al. Radiotherapy-induced malfunction in contemporary cardiovascular implantable electronic devices: Clinical incidence and predictors. *JAMA Oncol.* 2015;1:624–632.

39. Lester J, Evans L, Mayles P, et al. Management of cancer patients receiving radiotherapy with a cardiac implanted electronic device: A clinical guideline. London, United Kingdom: Radiotherapy Board of the Society And College Of Radiographers; 2015.

40. Gauter-Flekenstein B, Barthel C, Böttner S, et al. Effectivity and applicability of the German DEGRO/DGK-guideline for radiotherapy in CIED-bearing patients. *Radioth Oncol.* 2020;152:208–215.

41. Aslian H, Kron T, Watts T, et al. The effect of stereotactic body radiotherapy (SBRT) using flatness filter-free beams on cardiac implantable electronic devices (CIEDs) in clinical situations. *J Appl Clin Med Phys.* 2020;21:121–131.

42. Nakamura K, Aoyama T, Kameda N, et al. Effect of x-ray dose rates higher than 8 Gy/min on the functioning of cardiac implantable electronic devices. *J Radiat Res*. 2020;61:419–425.

43. Kry S, Bednarz B, Howell RM, et al. AAPM TG 158: Measurement and calculation of doses outside the treated volume from external-beam radiation therapy. *Med Phys.* 2017;44:e391–e429.

44. Yan H, Guo F, Zhu D, et al. On the use of bolus for pacemaker dose measurement and reduction in radiotherapy. *J Appl Clin Med Phys*. 2018;19:125–131.

45. Gomez DR, Peonis F, Finnix CC, et al. Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: Incidence and predictors. *Int J Radiat Oncol Biol Phys*. 2013;87:570–575.

46. Ueyama T, Arimura T, Ogino T, et al. Pacemaker malfunction associated with proton beam therapy: A report of two cases and review of literature: Does field-to-generator distance matter? *Oxford Med Cases Reports*. 2016;8:190–194.

47. Rodriguez F, Filimonov A, Henning A, et al. Radiation-induced efforts in multiprogrammable pacemakers and implantable defibrillators. *Pacing Clin Electrophysiol*. 1991;14:2143–2153.

48. Bitterman DS, Zei PC, Mark RH. Radiation safety and cardiovascular implantable electronic devices. *Int J Radiat Oncol Biol Phys*. 2018;102:243–246.

49. Matsubara H, Ezura T, Hashimoto Y, et al. Prediction of radiation-induced malfunction for cardiac implantable electronic devices (CIEDs). *Med Phys*. 2020;47:1489–1498.

50. Oshiro Y, Sugahara S, Noma M, et al. Proton beam therapy interference with implanted cardiac pacemakers. *Int J Radiat Oncol Biol Phys*. 2008;72:723–727.

51. Keseck M, Nyholm T, Asklund T. Radiotherapy and pacemaker: 80 Gy to target close to the device may be feasible. *EP Europace*. 2012;14:1595.

52. Zecchin M, Severgnini M, Fiorentino A, et al. Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy: A consensus document from Associazione Italiana Aritmiologica Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica (AIRO), Associazione Italiana Fisica Medica (AIFM). *Int J Cardiol*. 2018;255:175–183.

53. Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: Agility and collaboration toward a common goal. *J Natl Comprehensive Cancer Network*. 2020;20:1–4.

54. Cortiula F, Pettie A, Bartolletti M, et al. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. *Ann Oncol.* 2020;31:553–555.

55. Dobson R, Wright D. Management of cardiac implantable devices in patients undergoing radiotherapy. *Curr Probl Cancer*. 2018;42:443–448.

56. Brambatti M, Mathew R, Strang B, et al. Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy. *Heart Rhythm*. 2015;2:2148–2154.